Immunogenicity and Safety Study of Serum-Free Avonex
Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the immunogenicity of a serum-free pre-formulated solution of Avonex when given
to interferon beta naive patients with relapsing/remitting multiple sclerosis.